Poricoic acid A
Based on 1 publication(s) in Google Scholar
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.32%
- CAS No.: 137551-38-3
- Formule: C31H46O5
- Masse moléculaire:498.69
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Poricoic acid A
MoreVoir tous les produits spécifiques à Isoform AMPK
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| AZ-521 cell line | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| B16 | IC50 |
48.01 μg/mL
Compound: 8
|
Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTS assay
Cytotoxicity against mouse B16 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTS assay
|
[PMID: 39026645] |
| CCRF-CEM | IC50 |
>40 μM
Compound: 22
|
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 27808511] |
| DU-145 | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| HL-60 | IC50 |
>40 μM
Compound: 22
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 27808511] |
| HL-60 | IC50 |
38 μM
Compound: 1a
|
Cytotoxicity in human HL60 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human HL60 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| HL-60 | IC50 |
38 μM
Compound: 7
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 19746919] |
| K562 | IC50 |
>40 μM
Compound: 22
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 27808511] |
| MOLT-4 | IC50 |
>40 μM
Compound: 22
|
Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay
|
[PMID: 27808511] |
| OVCAR-3 | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human OVCAR3 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human OVCAR3 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| PANC-1 | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human PANC1 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human PANC1 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
| SK-BR-3 | IC50 |
>100 μM
Compound: 1a
|
Cytotoxicity in human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity in human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21250700] |
In Vitro
Poricoic acid A (10 μM) protects against hypoxia/reoxygenation (H/R)-induced injury in cultured renal NRK-52E cells[2].
Poricoic acid A (5-10 μM, 24 h) has inhibitory effects on NRK-49F viability dose-dependently[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Renal NRK-52E cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Reduced the level of NF-κB that transferred into the nucleus after H/R.
Resulted in stronger inhibitory effect on inflammatory pathway when combined with Melatonin.
Upregulated the HO-1 level that was reduced due to H/R.
In Vivo
Poricoic acid A (5-20 mg/kg, p.o., 1-2 w) ameliorates hyoertension and anaemia as well as improves kidney function in Nx-induced CKD rats[3].
Poricoic acid A (5-20 mg/kg, p.o., 1-2 w) significantly reduced renal fibrosis in UUO rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male IRI SD rats[2]
-
Dosage:10 mg/kg/day
-
Administration:Intragastric (i.g.), day 2 to 13 after reperfusion
-
Result:Significantly downregulated pro-fibrotic Gas6 protein level, and combined therapy with Melatonin performed better.
Significantly ameliorated the activation of NF-κB pathway.
Significantly attenuated the expression of ED-1 and CD3 in renal interstitium compared with IRI group.
Mitigated the downregulation of Nrf2 and its downstream targets in IRI rats.
Markedly reduced the deposition of collagen I and collagen III in renal interstitium.
-
Animal Model:Nx-induced CKD rats[3]
-
Dosage:5, 10, 20 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Ameliorated polyuria, elevated blood pressure, increased serum urea and creatinine levesl, reduced creatinine clearance and lowered body weight.
Suppressed aberrant synthesis and enhanced degradation of ECM in Nx rats.
Activated AMPK and suppressed TGF-β1/Smad3 pathway.
Chemical Information
-
CAS No. 137551-38-3
-
Appearance Solid
-
Masse moléculaire 498.69
-
Formule C31H46O5
-
Color White to off-white
-
SMILES
C[C@]12[C@@]([C@]([C@H](C(O)=O)CCC(C(C)C)=C)([H])[C@H](O)C1)(CC=C3C2=CC[C@@H](C(C)=C)[C@]3(C)CCC(O)=O)C
-
Synonyms
Poricoic acid A(F)
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Poricoic Acid A Attenuates Osteoarthritis Progression by Stabilizing PTEN and Suppressing PI3K/AKT Signaling. [Abstract]2026 Feb 14;27(4):1835. PMID: 41751971
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (200.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Dong H, et al. Enrichment and separation of antitumor triterpene acids from the epidermis of Poria cocos by pH-zone-refining counter-current chromatography and conventional high-speed counter-current chromatography. J Sep Sci. 2015 Jun;38(11):1977-82. [Content Brief]
[2]. Chen DQ, et al. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic Biol Med. 2019 Apr;134:484-497. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0053 mL | 10.0263 mL | 20.0525 mL | 50.1313 mL |
| 5 mM | 0.4011 mL | 2.0053 mL | 4.0105 mL | 10.0263 mL | |
| 10 mM | 0.2005 mL | 1.0026 mL | 2.0053 mL | 5.0131 mL | |
| 15 mM | 0.1337 mL | 0.6684 mL | 1.3368 mL | 3.3421 mL | |
| 20 mM | 0.1003 mL | 0.5013 mL | 1.0026 mL | 2.5066 mL | |
| 25 mM | 0.0802 mL | 0.4011 mL | 0.8021 mL | 2.0053 mL | |
| 30 mM | 0.0668 mL | 0.3342 mL | 0.6684 mL | 1.6710 mL | |
| 40 mM | 0.0501 mL | 0.2507 mL | 0.5013 mL | 1.2533 mL | |
| 50 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 1.0026 mL | |
| 60 mM | 0.0334 mL | 0.1671 mL | 0.3342 mL | 0.8355 mL | |
| 80 mM | 0.0251 mL | 0.1253 mL | 0.2507 mL | 0.6266 mL | |
| 100 mM | 0.0201 mL | 0.1003 mL | 0.2005 mL | 0.5013 mL |
Poricoic acid A Related Classifications
HY-N2995 Related Classifications
Powered by Bioz